IL319054A - נוגדנים ומקטעי נוגדנים לאוריסטאטין מונומתיל - Google Patents
נוגדנים ומקטעי נוגדנים לאוריסטאטין מונומתילInfo
- Publication number
- IL319054A IL319054A IL319054A IL31905425A IL319054A IL 319054 A IL319054 A IL 319054A IL 319054 A IL319054 A IL 319054A IL 31905425 A IL31905425 A IL 31905425A IL 319054 A IL319054 A IL 319054A
- Authority
- IL
- Israel
- Prior art keywords
- antibodies
- antibody fragments
- monomethyl auristatin
- auristatin
- monomethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263373367P | 2022-08-24 | 2022-08-24 | |
| US202363520689P | 2023-08-21 | 2023-08-21 | |
| PCT/US2023/072852 WO2024044709A2 (en) | 2022-08-24 | 2023-08-24 | Anti-monomethyl auristatin antibodies and antibody fragments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL319054A true IL319054A (he) | 2025-04-01 |
Family
ID=90014109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL319054A IL319054A (he) | 2022-08-24 | 2023-08-24 | נוגדנים ומקטעי נוגדנים לאוריסטאטין מונומתיל |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP4577568A2 (he) |
| JP (1) | JP2025528390A (he) |
| KR (1) | KR20250060232A (he) |
| CN (1) | CN120035610A (he) |
| AU (1) | AU2023329378A1 (he) |
| CA (1) | CA3265572A1 (he) |
| CO (1) | CO2025002048A2 (he) |
| CR (1) | CR20250060A (he) |
| DO (1) | DOP2025000040A (he) |
| GE (1) | GEAP202516711A (he) |
| IL (1) | IL319054A (he) |
| JO (1) | JOP20250041A1 (he) |
| MX (1) | MX2025002127A (he) |
| PE (1) | PE20251523A1 (he) |
| WO (1) | WO2024044709A2 (he) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025043019A1 (en) * | 2023-08-21 | 2025-02-27 | The Research Foundation For The State University Of New York | Slc4a1 (band 3) binding single domain antibodies for increased blood retention |
| WO2025252100A1 (zh) | 2024-06-05 | 2025-12-11 | 荣昌生物制药(烟台)股份有限公司 | 一种自带游离载荷回收单元的配体药物偶联物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201425336A (zh) * | 2012-12-07 | 2014-07-01 | Amgen Inc | Ｂｃｍａ抗原結合蛋白質 |
| WO2018177371A1 (en) * | 2017-03-29 | 2018-10-04 | Taipei Medical University | Antigen-specific t cells and uses thereof |
| EP3725802A4 (en) * | 2017-11-17 | 2021-08-11 | ABL Bio Inc. | Antibodies to alpha-synuclein and uses thereof |
| CN109912684A (zh) * | 2019-03-08 | 2019-06-21 | 联宁（苏州）生物制药有限公司 | 一种用于抗体药物偶联物的药物-连接子mc-mmaf的制备方法及其中间体 |
| WO2021113740A1 (en) * | 2019-12-04 | 2021-06-10 | The Research Foundation For The State University Of New York | Compositions and methods for reducing off-target toxicity of antibody drug conjugates |
-
2023
- 2023-08-24 JP JP2025511575A patent/JP2025528390A/ja active Pending
- 2023-08-24 AU AU2023329378A patent/AU2023329378A1/en active Pending
- 2023-08-24 CN CN202380069240.4A patent/CN120035610A/zh active Pending
- 2023-08-24 GE GEAP202516711A patent/GEAP202516711A/en unknown
- 2023-08-24 PE PE2025000438A patent/PE20251523A1/es unknown
- 2023-08-24 CR CR20250060A patent/CR20250060A/es unknown
- 2023-08-24 KR KR1020257009590A patent/KR20250060232A/ko active Pending
- 2023-08-24 EP EP23858316.5A patent/EP4577568A2/en active Pending
- 2023-08-24 WO PCT/US2023/072852 patent/WO2024044709A2/en not_active Ceased
- 2023-08-24 IL IL319054A patent/IL319054A/he unknown
- 2023-08-24 CA CA3265572A patent/CA3265572A1/en active Pending
-
2025
- 2025-02-21 DO DO2025000040A patent/DOP2025000040A/es unknown
- 2025-02-21 MX MX2025002127A patent/MX2025002127A/es unknown
- 2025-02-24 CO CONC2025/0002048A patent/CO2025002048A2/es unknown
- 2025-02-24 JO JOJO/P/2025/0041A patent/JOP20250041A1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GEAP202516711A (en) | 2025-06-10 |
| CO2025002048A2 (es) | 2025-07-17 |
| CR20250060A (es) | 2025-03-18 |
| EP4577568A2 (en) | 2025-07-02 |
| JOP20250041A1 (ar) | 2025-02-24 |
| PE20251523A1 (es) | 2025-06-05 |
| CA3265572A1 (en) | 2024-02-29 |
| KR20250060232A (ko) | 2025-05-07 |
| WO2024044709A2 (en) | 2024-02-29 |
| DOP2025000040A (es) | 2025-06-15 |
| AU2023329378A1 (en) | 2025-03-06 |
| CN120035610A (zh) | 2025-05-23 |
| WO2024044709A3 (en) | 2024-04-04 |
| MX2025002127A (es) | 2025-05-02 |
| JP2025528390A (ja) | 2025-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4010378A4 (en) | ANTICCR8 MONOCLONAL ANTIBODIES AND USES THEREOF | |
| IL315254A (he) | נוגדנים 3e10 אנושיים, וריאנטים ומקטעים שלהם קושרי אנטיגן | |
| IL319054A (he) | נוגדנים ומקטעי נוגדנים לאוריסטאטין מונומתיל | |
| AU2021462438B2 (en) | Anti-human interleukin-33 monoclonal antibody and use thereof | |
| IL319931A (he) | נוגדנים אנטי- cd122 ושימושים בהם | |
| SMT202600020T1 (it) | Anticorpi monoclonali anti-gprc5d e usi di essi | |
| IL314622A (he) | נוגדנים מואנשים כנגד Nectin-2 ותרופות מצומדות שלהם | |
| IL320586A (he) | נוגדן נגד trem2 ושימושים שלו | |
| IL317849A (he) | נוגדנים חד-שבטיים אנטי- slc34a2ושימושים בהם | |
| CA3250452A1 (en) | ANTI-5T4 ANTIBODIES AND THEIR USES | |
| IL316510A (he) | נוגדן אנטי-b7h3 ושימושיו | |
| EP4490199A4 (en) | MODIFIED ANTIBODIES AND THEIR USES | |
| IL310432A (he) | נוגדנים ומצומדי נוגדן ספציפיים לנקטין-4 ושיטות לשימוש בהם | |
| IL320972A (he) | נוגדנים אנטי-tfr1 ושימושים בהם | |
| GB202303531D0 (en) | Antibodies and uses thereof | |
| IL315029A (he) | נוגדנים חד-שבטיים אנטי- il-13ra2ושימושים בהם | |
| CA3299227A1 (en) | Sarbecovirus monoclonal antibodies and uses thereof | |
| CA3275669A1 (en) | Anti-slc1a4 monoclonal antibodies and uses thereof | |
| CA3269810A1 (en) | Anti-asgr1 monoclonal antibody and use thereof | |
| CA3290411A1 (en) | Modified antibodies, antibody fragments thereof, and antibody-drug conjugates | |
| HK40078970A (en) | Anti-tmprss2 antibodies and antigen-binding fragments | |
| CA3283282A1 (en) | Anti-5t4 antibodies and uses thereof | |
| CA3273041A1 (en) | Anti-5t4 antibodies and uses thereof | |
| CA3284137A1 (en) | Anti-gpvi antibodies and functional fragments thereof | |
| EP4296358A4 (en) | MONOCLONAL ANTI-TETRANOR-PGDM ANTIBODY AND USE THEREOF |